Search research articles
Contact Us
Filters
Showing results (61-70 of 95) with videos related to
Page
of 10
Sort By:
Cancer
|
July 3, 2023
A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma
Shetal A Patel, Michael K Gibson, Allison Deal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLC
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.
Clinical Lung Cancer
|
August 24, 2025
Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare© Study
Angela M Stover, Allison M Deal, Chaely J Medley, et al.
Frontiers in Oncology
|
August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
Corey J Langer, Edward S Kim, Eric C Anderson, et al.
Cancer Medicine
|
May 2, 2021
The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC
Jason Tasoulas, Nicholas R Lenze, Douglas Farquhar, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2018
Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy
Kevin A Pearlstein, Kyle Wang, Robert J Amdur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Cancer
|
September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 95) with videos related to
Sort By:
Page
of 10
Cancer
|
July 3, 2023
A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma
Shetal A Patel, Michael K Gibson, Allison Deal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLC
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.
Clinical Lung Cancer
|
August 24, 2025
Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare© Study
Angela M Stover, Allison M Deal, Chaely J Medley, et al.
Frontiers in Oncology
|
August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
Corey J Langer, Edward S Kim, Eric C Anderson, et al.
Cancer Medicine
|
May 2, 2021
The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC
Jason Tasoulas, Nicholas R Lenze, Douglas Farquhar, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2018
Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy
Kevin A Pearlstein, Kyle Wang, Robert J Amdur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Cancer
|
September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Page
of 10